Mw-Med Sp. z o.o.

The research at Mw-Med Sp. z o.o. focuses on exudative age‑related macular degeneration, a leading cause of vision loss, aiming to improve treatment outcomes for patients with submacular bleeding and neovascular disease.

• Vitrectomy combined with subretinal tissue‑plasminogen activator
• Intravitreal anti‑VEGF agents and gas tamponade
• Port Delivery System delivering ranibizumab
• Long‑term safety and efficacy assessments

Ongoing studies at the Cracow site evaluate innovative surgical and drug‑delivery approaches, seeking to reduce treatment burden and preserve visual function for individuals with wet AMD.